A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model

Trial Profile

A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Tavilermide (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Sponsors Mimetogen Pharmaceuticals
  • Most Recent Events

    • 17 Sep 2014 New trial record
    • 07 May 2012 Primary endpoint (Ocular surface damage assessed by corneal staining at 28 days) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top